Search Results

Your search for JULIA CIPRIANO, MS, CMPP matches 2 pages

Showing 1 - 2

By JULIA CIPRIANO, MS, CMPP / November 2025 / ESMO Congress 2025

Final Overall Survival Confirms Benefit of Durvalumab Plus FLOT in Resectable Gastric and Gastroesophageal Junction Adenocarcinomas

The addition of the PD-L1–targeting monoclonal antibody durvalumab to conventional perioperative chemotherapy with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) resulted in a statistically significant and clinically meaningful improvement in overall survival, with benefit seen...

head and neck cancer

By Julia Cipriano, MS, CMPP / November 2025

Oropharyngeal Cancer in the United States: Recent Estimates and Future Trends

Based on the results of a cross-sectional epidemiologic analysis published in JAMA Network Open, the incidence of oropharyngeal cancer has increased among older individuals in the United States. According to Cao et al, those with localized disease appeared to be undertreated, indicating the need...

Nov

Today In Oncology

Search Results

Your search for JULIA CIPRIANO, MS, CMPP matches 2 pages

Final Overall Survival Confirms Benefit of Durvalumab Plus FLOT in Resectable Gastric and Gastroesophageal Junction Adenocarcinomas

Oropharyngeal Cancer in the United States: Recent Estimates and Future Trends

Basser Center for BRCA Announces Two Award Winners

Extended ERSPC Analysis Demonstrates Long-Term Mortality Benefit of PSA Screening for Prostate Cancer

RCC: Lenvatinib/Everolimus Extends PFS After PD-1 Inhibition

Final Overall Survival Confirms Benefit of Durvalumab Plus FLOT in Resectable Gastric and Gastroesophageal Junction Adenocarcinomas

Lung Cancer Advancements Are Saving More Lives Than Ever but Funding Cuts May Hinder Progress